Saudi German Health makes SAR 264.1M profit in 9M 2025, SAR 40.3M in Q3

02/11/2025 Argaam Exclusive

View other reports

Middle East Healthcare Co. (Saudi German Health) posted net earnings of SAR 264.1 million for the first nine months of 2025, up from SAR 170.7 million in the year before.

Financials (M)

Item	9m 2024	9m 2025	Change‬
Revenues	2,133.94	2,293.84	7.5 %
Gross Income	831.82	875.64	5.3 %
Operating Income	339.24	300.33	(11.5 %)
Net Income	170.71	264.09	54.7 %
Average Shares	92.04	92.04	-
Earnings Per Share before unusual items (Riyals)	1.64	1.63	(0.8 %)
EPS (Riyal)	1.85	2.87	54.7 %

Elevated revenues mainly lifted the Saudi-listed company’s nine-month profit increase, supported by growth in the total number of inpatient admissions and outpatient visits, as well as the expansion of bed capacity across selected facilities within the group during the current period.

It also benefited from an exceptional contract awarded by the Ministry of Health to operate Mina Emergency Hospital II during the 2025 Hajj season. This is besides lower finance costs due to improved leverage and declining interest rates.

Current Quarter Comparison (M)

Compared With The

Item	Q3 2024	Q3 2025	Change‬
Revenues	732.07	768.97	5.0 %
Gross Income	292.90	283.95	(3.1 %)
Operating Income	115.88	87.44	(24.5 %)
Net Income	63.84	40.29	(36.9 %)
Average Shares	92.04	92.04	-
Earnings Per Share before unusual items (Riyal)	0.69	0.44	(36.9 %)
EPS (Riyal)	0.69	0.44	(36.9 %)

Item	Q2 2025	Q3 2025	Change‬
Revenues	791.13	768.97	(2.8 %)
Gross Income	308.04	283.95	(7.8 %)
Operating Income	111.34	87.44	(21.5 %)
Net Income	63.67	40.29	(36.7 %)
Average Shares	92.04	92.04	-
Earnings Per Share before unusual items (Riyal)	0.69	0.44	(36.7 %)
EPS (Riyal)	0.69	0.44	(36.7 %)

Moreover, in 9M 2025, Saudi German Health generated a one-off capital gain of SAR 114 million from the sale of an unused land plot in Riyadh, compared to a capital gain of SAR 19.6 million recorded last year.

However, the Saudi healthcare provider’s net profits tumbled by 36.9% to SAR 40.3 million in Q3 2025, versus SAR 63.84 million in the same quarter last year.

This quarterly earnings drop was mainly attributed to higher operating costs and increased staff expenses resulting from new hires linked to capacity expansion across several branches and the introduction of new subspecialties across various departments.

General, selling, and marketing expenses also rose following the implementation of the “NPHIES” system for Ministry of Health billing starting April 2025, while the company also recorded a higher share of losses from an associate, Al-Sobh New Medical Co., which is 22.4% owned by the group, after it commenced operations on Sept. 15.

This was partly offset by higher revenues during the quarter, supported by increased inpatient and outpatient volumes and expanded bed capacity in selected facilities.

On a quarterly basis, the three-month bottom line shrank from SAR 63.67 million in Q2 2025.

Total shareholders' equity, after minority interest, reached SAR 1.84 billion by the end of Sept. 30, 2025, edging up from SAR 1.49 billion a year earlier.

View more financial results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2016	421.52	7.6 %	216.62	3.7 %	103.68	0.8 %
Q2 2016	410.07	10.2 %	212.49	4.2 %	76.56	(14.2 %)
Q3 2016	379.09	7.6 %	199.40	8.8 %	91.10	3.3 %
Q4 2016	404.96	(3.3 %)	199.88	(6.6 %)	87.04	(11.1 %)
2016	1,615.64	5.3 %	828.39	2.3 %	358.37	(5.2 %)
Q1 2017	393.53	(6.6 %)	180.47	(16.7 %)	107.04	3.2 %
Q2 2017	351.28	(14.3 %)	138.63	(34.8 %)	58.97	(23.0 %)
Q3 2017	352.98	(6.9 %)	133.30	(33.1 %)	55.70	(38.9 %)
Q4 2017	364.60	(10.0 %)	145.47	(27.2 %)	73.06	(16.1 %)
2017	1,462.39	(9.5 %)	597.87	(27.8 %)	294.77	(17.7 %)
Q1 2018	395.11	0.4 %	160.42	(11.1 %)	85.82	(19.8 %)
Q2 2018	346.13	(1.5 %)	116.91	(15.7 %)	31.66	(46.3 %)
Q3 2018	338.77	(4.0 %)	111.87	(16.1 %)	21.29	(61.8 %)
Q4 2018	310.68	(14.8 %)	111.56	(23.3 %)	23.96	(67.2 %)
2018	1,390.69	(4.9 %)	500.75	(16.2 %)	162.73	(44.8 %)
Q1 2019	350.18	(11.4 %)	101.63	(36.6 %)	18.31	(78.7 %)
Q2 2019	353.20	2.0 %	102.76	(12.1 %)	7.58	(76.0 %)
Q3 2019	386.76	14.2 %	119.96	7.2 %	33.31	56.5 %
Q4 2019	406.51	30.8 %	148.59	33.2 %	44.06	83.9 %
2019	1,496.65	7.6 %	472.93	(5.6 %)	103.27	(36.5 %)
Q1 2020	436.31	24.6 %	146.86	44.5 %	24.36	33.0 %
Q2 2020	373.26	5.7 %	120.49	17.3 %	23.73	212.9 %
Q3 2020	492.13	27.2 %	171.91	43.3 %	42.12	26.4 %
Q4 2020	448.89	10.4 %	139.12	(6.4 %)	17.20	(61.0 %)
2020	1,750.59	17.0 %	578.37	22.3 %	107.41	4.0 %
Q1 2021	418.37	(4.1 %)	123.16	(16.1 %)	(0.04)	(100.2 %)
Q2 2021	456.57	22.3 %	152.64	26.7 %	20.12	(15.2 %)
Q3 2021	498.73	1.3 %	172.27	0.2 %	27.46	(34.8 %)
Q4 2021	498.95	11.2 %	160.11	15.1 %	(7.03)	(140.9 %)
2021	1,872.62	7.0 %	608.18	5.2 %	40.50	(62.3 %)
Q1 2022	513.32	22.7 %	165.02	34.0 %	35.28	90551.0 %
Q2 2022	508.09	11.3 %	158.77	4.0 %	21.77	8.2 %
Q3 2022	512.37	2.7 %	152.21	(11.6 %)	26.26	(4.4 %)
Q4 2022	617.96	23.9 %	204.01	27.4 %	57.96	924.3 %
2022	2,151.74	14.9 %	680.01	11.8 %	140.34	246.5 %
Q1 2023	637.99	24.3 %	225.50	36.6 %	76.51	116.9 %
Q2 2023	624.33	22.9 %	228.63	44.0 %	68.99	216.9 %
Q3 2023	671.05	31.0 %	266.33	75.0 %	109.85	318.4 %
Q4 2023	719.81	16.5 %	293.96	44.1 %	68.62	18.4 %
2023	2,653.17	23.3 %	1,014.41	49.2 %	323.97	130.8 %
Q1 2024	689.21	8.0 %	259.86	15.2 %	117.64	53.8 %
Q2 2024	712.66	14.1 %	279.07	22.1 %	105.73	53.3 %
Q3 2024	732.07	9.1 %	292.90	10.0 %	115.88	5.5 %
Q4 2024	748.88	4.0 %	282.07	(4.0 %)	101.69	48.2 %
2024	2,882.82	8.7 %	1,113.90	9.8 %	440.93	36.1 %
Q1 2025	733.74	6.5 %	283.65	9.2 %	101.55	(13.7 %)
Q2 2025	791.13	11.0 %	308.04	10.4 %	111.34	5.3 %
Q3 2025	768.97	5.0 %	283.95	(3.1 %)	87.44	(24.5 %)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2015	1,534.53	9.7 %	810.13	8.1 %	378.20	20.8 %
2016	1,615.64	5.3 %	828.39	2.3 %	358.37	(5.2 %)
2017	1,462.39	(9.5 %)	597.87	(27.8 %)	294.77	(17.7 %)
2018	1,390.69	(4.9 %)	500.75	(16.2 %)	162.73	(44.8 %)
2019	1,496.65	7.6 %	472.93	(5.6 %)	103.27	(36.5 %)
2020	1,750.59	17.0 %	578.37	22.3 %	107.41	4.0 %
2021	1,872.62	7.0 %	608.18	5.2 %	40.50	(62.3 %)
2022	2,151.74	14.9 %	680.01	11.8 %	140.34	246.5 %
2023	2,653.17	23.3 %	1,014.41	49.2 %	323.97	130.8 %
2024	2,882.82	8.7 %	1,113.90	9.8 %	440.93	36.1 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
Q1 2016	104.20	(1.1 %)	1.13	-	104.20	1.13
Q2 2016	74.07	(19.3 %)	0.80	-	74.07	0.80
Q3 2016	99.64	9.8 %	1.08	-	99.64	1.08
Q4 2016	84.73	(17.2 %)	0.92	-	84.73	0.92
2016	362.64	(7.1 %)	3.94	-	362.64	3.94
Q1 2017	109.97	5.5 %	1.19	-	109.97	1.19
Q2 2017	61.95	(16.4 %)	0.67	-	61.95	0.67
Q3 2017	64.88	(34.9 %)	0.70	-	64.88	0.70
Q4 2017	82.69	(2.4 %)	0.90	-	82.69	0.90
2017	319.49	(11.9 %)	3.47	-	319.49	3.47
Q1 2018	87.13	(20.8 %)	0.95	-	87.13	0.95
Q2 2018	34.27	(44.7 %)	0.37	-	34.27	0.37
Q3 2018	20.16	(68.9 %)	0.22	-	20.16	0.22
Q4 2018	30.69	(62.9 %)	0.33	-	30.69	0.33
2018	172.25	(46.1 %)	1.87	-	172.25	1.87
Q1 2019	14.59	(83.3 %)	0.16	-	14.59	0.16
Q2 2019	12.28	(64.2 %)	0.13	-	12.28	0.13
Q3 2019	33.23	64.8 %	0.36	-	33.23	0.36
Q4 2019	37.47	22.1 %	0.41	(8.00)	45.47	0.49
2019	97.57	(43.4 %)	1.06	(8.00)	105.57	1.15
Q1 2020	21.18	45.2 %	0.23	-	21.18	0.23
Q2 2020	16.35	33.2 %	0.18	-	16.35	0.18
Q3 2020	34.91	5.1 %	0.38	-	34.91	0.38
Q4 2020	9.54	(74.5 %)	0.10	-	9.54	0.10
2020	81.99	(16.0 %)	0.89	-	81.99	0.89
Q1 2021	12.10	(42.9 %)	0.13	17.53	(5.43)	(0.06)
Q2 2021	9.14	(44.1 %)	0.10	(0.48)	9.62	0.10
Q3 2021	14.35	(58.9 %)	0.16	(4.16)	18.51	0.20
Q4 2021	(18.39)	(292.8 %)	(0.20)	0.84	(19.24)	(0.21)
2021	17.20	(79.0 %)	0.19	13.74	3.46	0.04
Q1 2022	20.49	69.3 %	0.22	-	20.49	0.22
Q2 2022	10.43	14.1 %	0.11	-	10.43	0.11
Q3 2022	11.11	(22.6 %)	0.12	-	11.11	0.12
Q4 2022	33.16	280.3 %	0.36	-	33.16	0.36
2022	75.18	337.1 %	0.82	-	75.18	0.82
Q1 2023	50.12	144.6 %	0.54	-	50.12	0.54
Q2 2023	40.25	286.0 %	0.44	-	40.25	0.44
Q3 2023	53.30	379.9 %	0.58	-	53.30	0.58
Q4 2023	(126.64)	(481.9 %)	(1.38)	(152.46)	25.82	0.28
2023	17.04	(77.3 %)	0.19	(152.46)	169.50	1.84
Q1 2024	44.00	(12.2 %)	0.48	-	44.00	0.48
Q2 2024	62.88	56.2 %	0.68	19.37	43.51	0.47
Q3 2024	63.84	19.8 %	0.69	-	63.84	0.69
Q4 2024	107.14	184.6 %	1.16	45.45	61.69	0.67
2024	282.00	1555.1 %	3.06	64.82	217.19	2.36
Q1 2025	160.13	263.9 %	1.74	114.00	46.13	0.50
Q2 2025	63.67	1.3 %	0.69	-	63.67	0.69
Q3 2025	40.29	(36.9 %)	0.44	-	40.29	0.44

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS(Riyal)
2015	390.25	17.6 %	4.24	-	390.25	4.24
2016	362.64	(7.1 %)	3.94	-	362.64	3.94
2017	319.49	(11.9 %)	3.47	-	319.49	3.47
2018	172.25	(46.1 %)	1.87	-	172.25	1.87
2019	97.57	(43.4 %)	1.06	(8.00)	105.57	1.15
2020	81.99	(16.0 %)	0.89	-	81.99	0.89
2021	17.20	(79.0 %)	0.19	13.74	3.46	0.04
2022	75.18	337.1 %	0.82	-	75.18	0.82
2023	17.04	(77.3 %)	0.19	(152.46)	169.50	1.84
2024	282.00	1555.1 %	3.06	64.82	217.19	2.36

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	52.27 %	27.77 %	24.87 %
Q2 2016	51.57 %	26.50 %	23.17 %
Q3 2016	51.71 %	26.41 %	23.34 %
Q4 2016	51.27 %	26.12 %	22.45 %
2016	51.27 %	26.12 %	22.45 %
Q1 2017	49.90 %	26.91 %	23.20 %
Q2 2017	46.99 %	27.02 %	23.30 %
Q3 2017	43.41 %	25.39 %	21.40 %
Q4 2017	40.88 %	25.40 %	21.85 %
2017	40.88 %	25.40 %	21.85 %
Q1 2018	39.47 %	24.17 %	20.26 %
Q2 2018	38.12 %	22.54 %	18.44 %
Q3 2018	37.01 %	20.57 %	15.52 %
Q4 2018	36.01 %	18.10 %	12.39 %
2018	36.01 %	18.10 %	12.39 %
Q1 2019	32.84 %	13.74 %	7.41 %
Q2 2019	31.62 %	12.25 %	5.74 %
Q3 2019	31.12 %	12.85 %	6.48 %
Q4 2019	31.60 %	13.48 %	7.05 %
2019	31.60 %	13.48 %	7.05 %
Q1 2020	32.74 %	13.41 %	7.09 %
Q2 2020	33.43 %	14.66 %	7.25 %
Q3 2020	34.41 %	14.80 %	6.90 %
Q4 2020	33.04 %	13.40 %	4.68 %
2020	33.04 %	13.40 %	4.68 %
Q1 2021	32.01 %	12.65 %	3.20 %
Q2 2021	32.32 %	11.91 %	2.68 %
Q3 2021	32.22 %	11.12 %	1.77 %
Q4 2021	32.48 %	9.71 %	0.18 %
2021	32.48 %	9.71 %	0.18 %
Q1 2022	33.04 %	10.93 %	1.49 %
Q2 2022	32.50 %	10.71 %	1.50 %
Q3 2022	31.29 %	10.75 %	1.12 %
Q4 2022	31.60 %	13.35 %	3.49 %
2022	31.60 %	13.31 %	3.49 %
Q1 2023	32.53 %	15.00 %	4.60 %
Q2 2023	33.87 %	16.89 %	5.63 %
Q3 2023	36.23 %	19.39 %	6.93 %
Q4 2023	38.23 %	19.36 %	6.39 %
2023	38.23 %	19.36 %	6.39 %
Q1 2024	38.78 %	20.72 %	6.04 %
Q2 2024	39.36 %	21.54 %	5.97 %
Q3 2024	39.45 %	21.60 %	6.21 %
Q4 2024	38.64 %	22.81 %	7.39 %
2024	38.64 %	22.81 %	7.53 %
Q1 2025	38.86 %	22.14 %	7.35 %
Q2 2025	38.81 %	22.01 %	7.83 %
Q3 2025	38.05 %	-	6.96 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2015	52.79 %	28.05 %	25.43 %
2016	51.27 %	26.12 %	22.45 %
2017	40.88 %	25.40 %	21.85 %
2018	36.01 %	18.10 %	12.39 %
2019	31.60 %	13.48 %	7.05 %
2020	33.04 %	13.40 %	4.68 %
2021	32.48 %	9.71 %	0.18 %
2022	31.60 %	13.31 %	3.49 %
2023	38.23 %	19.36 %	6.39 %
2024	38.64 %	22.81 %	7.53 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2016	51.39 %	28.30 %	24.72 %
Q2 2016	51.82 %	22.50 %	18.06 %
Q3 2016	52.60 %	28.28 %	26.29 %
Q4 2016	49.36 %	25.48 %	20.92 %
Q1 2017	45.86 %	31.64 %	27.94 %
Q2 2017	39.46 %	22.25 %	17.64 %
Q3 2017	37.76 %	21.46 %	18.38 %
Q4 2017	39.90 %	25.53 %	22.68 %
Q1 2018	40.60 %	27.04 %	22.05 %
Q2 2018	33.78 %	15.35 %	9.90 %
Q3 2018	33.02 %	13.01 %	5.95 %
Q4 2018	35.91 %	15.33 %	9.88 %
Q1 2019	29.02 %	11.44 %	4.17 %
Q2 2019	29.09 %	9.62 %	3.48 %
Q3 2019	31.02 %	15.07 %	8.59 %
Q4 2019	36.55 %	17.05 %	11.18 %
Q1 2020	33.66 %	11.59 %	4.85 %
Q2 2020	32.28 %	15.23 %	4.38 %
Q3 2020	34.93 %	15.45 %	7.09 %
Q4 2020	30.99 %	11.40 %	2.13 %
Q1 2021	29.44 %	8.41 %	(1.30 %)
Q2 2021	33.43 %	11.79 %	2.11 %
Q3 2021	34.54 %	12.53 %	3.71 %
Q4 2021	32.09 %	6.10 %	(3.86 %)
Q1 2022	32.15 %	13.30 %	3.99 %
Q2 2022	31.25 %	10.84 %	2.05 %
Q3 2022	29.71 %	12.63 %	2.17 %
Q4 2022	33.01 %	16.05 %	5.37 %
Q1 2023	35.34 %	19.20 %	7.86 %
Q2 2023	36.62 %	18.87 %	6.45 %
Q3 2023	39.69 %	23.14 %	7.94 %
Q4 2023	40.84 %	16.42 %	3.59 %
Q1 2024	37.70 %	24.52 %	6.38 %
Q2 2024	39.16 %	22.31 %	6.11 %
Q3 2024	40.01 %	23.24 %	8.72 %
Q4 2024	37.67 %	21.31 %	8.24 %
Q1 2025	38.66 %	21.72 %	6.29 %
Q2 2025	38.94 %	21.79 %	8.05 %
Q3 2025	36.93 %	-	5.24 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
Q1 2016	92.04	4.23	4.23	16.39
Q2 2016	92.04	4.03	4.03	15.20
Q3 2016	92.04	4.13	4.13	16.43
Q4 2016	92.04	3.94	3.94	17.32
Q1 2017	92.04	4.00	4.00	18.46
Q2 2017	92.04	3.87	3.87	17.09
Q3 2017	92.04	3.49	3.49	17.74
Q4 2017	92.04	3.47	3.47	15.75
Q1 2018	92.04	3.22	3.22	16.69
Q2 2018	92.04	2.92	2.92	15.07
Q3 2018	92.04	2.44	2.44	15.29
Q4 2018	92.04	1.87	1.87	15.71
Q1 2019	92.04	1.08	1.08	15.87
Q2 2019	92.04	0.84	0.84	16.00
Q3 2019	92.04	0.99	0.99	16.36
Q4 2019	92.04	1.06	1.15	16.54
Q1 2020	92.04	1.13	1.22	16.77
Q2 2020	92.04	1.18	1.26	16.95
Q3 2020	92.04	1.19	1.28	17.33
Q4 2020	92.04	0.89	0.89	13.38
Q1 2021	92.04	0.79	0.60	13.51
Q2 2021	92.04	0.71	0.53	13.61
Q3 2021	92.04	0.49	0.35	13.77
Q4 2021	92.04	0.19	0.04	13.66
Q1 2022	92.04	0.28	0.32	13.89
Q2 2022	92.04	0.29	0.33	13.92
Q3 2022	92.04	0.26	0.25	14.04
Q4 2022	92.04	0.82	0.82	14.44
Q1 2023	92.04	1.14	1.14	15.37
Q2 2023	92.04	1.46	1.46	15.82
Q3 2023	92.04	1.92	1.92	16.41
Q4 2023	92.04	0.19	1.84	14.34
Q1 2024	92.04	0.12	1.78	14.83
Q2 2024	92.04	0.36	1.81	15.55
Q3 2024	92.04	0.48	1.92	16.25
Q4 2024	92.04	3.02	2.31	17.67
Q1 2025	92.04	4.28	2.34	19.41
Q2 2025	92.04	4.29	2.56	19.60
Q3 2025	92.04	4.03	2.30	20.03

Period	Shares Outstanding (M)	EPS (Riyal)	Earnings Per Share before unusual items (Riyal)	Book Value (BV)
2015	92.04	4.24	4.24	14.70
2016	92.04	3.94	3.94	17.32
2017	92.04	3.47	3.47	15.75
2018	92.04	1.87	1.87	15.71
2019	92.04	1.06	1.15	16.54
2020	92.04	0.89	0.89	13.38
2021	92.04	0.19	0.04	13.66
2022	92.04	0.82	0.82	14.44
2023	92.04	0.19	1.84	14.34
2024	92.04	3.06	2.36	17.67

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Recurring P/E	Price/book
Q1 2016	17.17	17.17	4.43
Q2 2016	17.16	17.16	4.56
Q3 2016	12.41	12.41	3.12
Q4 2016	18.62	18.62	4.23
Q1 2017	18.48	18.48	4.01
Q2 2017	19.45	19.45	4.41
Q3 2017	17.98	17.98	3.54
Q4 2017	15.52	15.52	3.42
Q1 2018	17.90	17.90	3.46
Q2 2018	20.02	20.02	3.88
Q3 2018	15.00	15.00	2.39
Q4 2018	17.34	17.34	2.07
Q1 2019	29.49	29.49	2.01
Q2 2019	32.63	32.63	1.72
Q3 2019	26.36	26.36	1.59
Q4 2019	28.02	25.89	1.80
Q1 2020	22.49	20.89	1.52
Q2 2020	25.77	23.99	1.79
Q3 2020	30.69	28.61	2.11
Q4 2020	39.35	39.35	2.62
Q1 2021	44.44	58.50	2.60
Q2 2021	54.85	74.08	2.88
Q3 2021	77.28	More than 100	2.75
Q4 2021	More than 100	More than 100	2.32
Q1 2022	More than 100	More than 100	2.34
Q2 2022	More than 100	98.17	2.31
Q3 2022	More than 100	More than 100	1.94
Q4 2022	31.16	31.16	1.76
Q1 2023	33.06	33.06	2.45
Q2 2023	48.33	48.33	4.47
Q3 2023	28.68	28.68	3.36
Q4 2023	More than 100	47.95	6.16
Q1 2024	More than 100	55.77	6.68
Q2 2024	More than 100	48.39	5.63
Q3 2024	More than 100	37.61	4.46
Q4 2024	22.76	29.68	3.89
Q1 2025	16.00	29.30	3.53
Q2 2025	13.25	22.23	2.90
Q3 2025	14.18	24.86	2.86

Period	P/E	Recurring P/E	Price/book
2015	-	-	-
2016	18.62	18.62	4.23
2017	15.52	15.52	3.42
2018	17.34	17.34	2.07
2019	28.02	25.89	1.80
2020	39.34	39.34	2.62
2021	More than 100	More than 100	2.32
2022	31.16	31.16	1.76
2023	More than 100	47.95	6.16
2024	22.42	29.11	3.89

Business Segments (Million)

Compared With The

Period	Inpatient clinics	Outpatient clinics	Pharmacy Sales	Others
Q1 2016	241.22	100.20	73.04	7.06
Q2 2016	229.99	99.85	72.93	7.31
Q3 2016	224.32	89.88	62.16	2.72
Q4 2016	220.91	107.73	72.64	3.69
Q1 2017	242.80	104.89	71.94	4.27
Q2 2017	224.48	92.89	70.77	3.54
Q3 2017	133.39	85.39	60.16	3.27
Q4 2017	172.44	114.51	71.35	6.30
Q1 2018	214.32	109.10	68.50	3.20
Q2 2018	188.62	79.63	76.10	1.78
Q3 2018	184.16	98.93	53.64	2.04
Q4 2018	147.36	97.71	61.91	3.70
Q1 2019	181.07	97.28	67.29	4.54
Q2 2019	185.66	95.13	68.96	3.44
Q3 2019	223.51	95.92	64.81	2.51
Q4 2019	222.02	111.18	69.80	3.51
Q1 2020	264.27	98.09	71.34	2.60
Q2 2020	238.16	70.59	61.71	2.81
Q3 2020	301.73	111.20	76.35	2.85
Q4 2020	281.15	110.99	74.56	3.81
Q1 2021	236.94	115.00	61.88	4.54
Q2 2021	284.69	102.17	67.31	2.40
Q3 2021	292.19	139.00	61.71	5.83
Q4 2021	284.48	135.06	74.52	4.89
Q1 2022	290.29	141.03	78.90	3.10
Q2 2022	294.67	138.11	73.11	2.20
Q3 2022	293.31	145.39	71.94	1.74
Q4 2022	360.72	163.35	89.59	4.30
Q1 2023	369.08	176.60	90.42	1.88
Q2 2023	366.84	172.86	76.94	7.70
Q3 2023	404.17	180.18	89.81	(3.12)
Q4 2023	405.24	210.55	103.89	0.13
Q1 2024	393.57	205.97	89.67	-
Q2 2024	408.47	202.81	98.26	3.12
Q3 2024	411.27	219.75	98.37	2.69
Q4 2024	414.82	224.14	106.95	2.97
Q1 2025	428.48	210.34	94.85	0.07
Q2 2025	422.10	260.61	107.25	1.17

Period	Inpatient clinics	Outpatient clinics	Pharmacy Sales	Others
2015	857.25	383.67	277.02	16.59
2016	916.44	397.66	280.76	20.77
2017	773.12	397.68	274.21	17.38
2018	734.45	385.37	260.14	10.73
2019	812.27	399.51	270.86	14.01
2020	1,085.30	390.88	283.96	12.07
2021	1,098.30	491.24	265.42	17.66
2022	1,238.98	587.88	313.54	11.34
2023	1,545.33	740.19	361.06	6.59
2024	1,628.12	852.68	393.25	8.77

Analysts Estimates (Million)

Item	Profit (Expected)	Profit (Actual)	Change
Average	62.17	40.29

Estimates vs Actual (Million)

Item	Profit (Expected)	Profit (Actual)
United Securities Company	51.00	40.29
SNB Capital	66.20	40.29
AlJazira Capital	69.30	40.29

Financial Ratios

	Current
Market Cap (M Riyal)	4,417.92
Enterprise Value (EV) (M Riyal)	6,768.65
Shares Outstanding ((M))	92.04
EPS ( Riyal) (TTM)	4.03
Book Value (BV) ( Riyal)	20.03
Par Value ( Riyal)	10.00
Recurring P/E	20.86
P/E (TTM)	11.90
Price/book	2.40
Return on Average Assets (%) (TTM)	7.1
Return on Average Equity (%) (TTM)	22.2
EV/adj EBITDA	-
EV/Revenues	2.22

Middle East Healthcare Co. (SAUDI GERMAN HEALTH)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Saudi German Health makes SAR 264.1M profit in 9M 2025, SAR 40.3M in Q3

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2025 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Middle East Healthcare Co. (SAUDI GERMAN HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Saudi German Health makes SAR 264.1M profit in 9M 2025, SAR 40.3M in Q3

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q2 2025

Revenue by Business Segment (Latest) 2025 Q3

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Middle East Healthcare Co. (SAUDI GERMAN HEALTH)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)